Central visual acuity is usually maintained until late in the course of glaucoma. Ten patients (5 men, 5 women) between the ages of 25 and 79 were found to have decreased visual acuity associated with central or centrocaecal scotomas early in their course. Five patients had chronic open-angle glucoma, three and pigmentary glaucoma, one and juvenile glaucoma, and one had Axenfeld's syndrome. A Marcus Gunn pupil was present in all six patients not on miotics. Most lost central acuity at pressures under 30 mmHg. Seven patients had vision of 20/200 or less. All with marked visual loss had a cup disc rate of .8 or greater. Other causes were carefully ruled out. Proposed mechanisms for the development of these central defects include either double Bjerrum scotomas which extend centrally or early papillomacular bundle involvement due to temporal cupping. This study demonstrates that decreased vision with associated central field loss can be a relatively early finding in glaucoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0161-6420(85)33938-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating optic system compression in sellar tumors: A novel application of quantitative pupillometry.
Acta Neurochir (Wien)
December 2024
Medical Faculty of Heidelberg University, Heidelberg, Germany.
Introduction: Tumorous growths in the sellar region pose significant clinical challenges due to their proximity to critical visual structures such as the optic chiasm and optic nerves. Given their proximity to the optic system, these tumors are often diagnosed due to a progressive decrease in visual acuity. Thus, surgical intervention is crucial to prevent irreversible damage, as timely decompression can halt the progression of edema and subsequent optic atrophy.
View Article and Find Full Text PDFOutliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners.
Clin Exp Ophthalmol
December 2024
The Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Background: We aimed to describe a 2-year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).
Methods: A multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012-2022 tracked in the Fight Retinal Blindness! registry.
Results: We identified 3 outlying 'intensive' practitioners (managing 350/1110 eyes [32%]), 22 'typical' practitioners (604/1110, [54%]) and 4 outlying 'relaxed' practitioners (156/1110, [14%]) with respective 24-month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.
[Functional outcomes of various aberrational extended depth-of-focus intraocular lenses].
Vestn Oftalmol
December 2024
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Purpose: This study compares the functional outcomes of correction using two different types of aberrational extended depth-of-focus (EDOF) intraocular lenses (IOLs).
Material And Methods: The study was conducted in two standardized groups (20 patients, 20 eyes in each group). Patients in group 1 were implanted EDOF IOL I, in group 2 - EDOF IOL II.
[Combined approach to cataract surgery in keratoconus].
Vestn Oftalmol
December 2024
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Preparation for cataract surgery in patients with keratoconus (KC) is associated with particular challenges: calculating the optical power of the intraocular lens (IOL), selecting the appropriate IOL model, and considering additional interventions aimed at stabilizing KC and reducing irregular astigmatism. This article presents a fundamentally new approach to combined treatment of KC with cataract, consisting of two stages: first, performing bandage therapeutic-optical keratoplasty (BTOK), followed by cataract phacoemulsification as the second stage.
View Article and Find Full Text PDFThe introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!